Standard BioTools
LAB
145 hedge funds and large institutions have $719M invested in Standard BioTools in 2024 Q1 according to their latest regulatory filings, with 72 funds opening new positions, 47 increasing their positions, 13 reducing their positions, and 13 closing their positions.
311,000% more call options, than puts
Call options by funds: $3.11M | Put options by funds: $1K
519% more capital invested
Capital invested by funds: $116M → $719M (+$603M)
454% more first-time investments, than exits
New positions opened: 72 | Existing positions closed: 13
262% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 13
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
69% more funds holding
Funds holding: 86 → 145 (+59)
25.84% more ownership
Funds ownership: 65.62% → 91.46% (+26%)
Top Buyers
| 1 |
CC
Casdin Capital
New York
|
+$147M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$142M |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$31.5M |
| 4 |
Millennium Management
New York
|
+$31.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.5M |
Top Sellers
| 1 |
CP
Caligan Partners
New York
|
-$15.6M |
| 2 |
HBWM
Hollow Brook Wealth Management
Katonah,
New York
|
-$4.14M |
| 3 |
BFM
Boothbay Fund Management
New York
|
-$1.15M |
| 4 |
Morgan Stanley
New York
|
-$578K |
| 5 |
HI
HBK Investments
Dallas,
Texas
|
-$333K |
LAB Hedge Fund Activity: Q1 2024 in Review
145 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q1 2024, worth a combined $719M — up 519% from $116M a quarter earlier.
Buyers outnumbered sellers: 72 funds opened new LAB positions and 13 closed out — a net gain of 59 holders — while 47 added to existing stakes and 13 trimmed.
The largest buyer was Casdin Capital, adding an estimated $147M. The largest seller was Caligan Partners, exiting entirely with an estimated $15.6M sold.
- 145 institutional investors held Standard BioTools (LAB) as of Q1 2024, up from 86 in Q4 2023.
- Funds reported $719M of Standard BioTools stock for Q1 2024, up 519% quarter-over-quarter.
- 72 funds opened new Standard BioTools positions in Q1 2024 and 13 closed out, a net change of +59 holders.
- The largest Standard BioTools buyer in Q1 2024 was Casdin Capital, an estimated $147M added.
- The largest Standard BioTools seller in Q1 2024 was Caligan Partners, an estimated $15.6M sold.
Based on aggregated 13F filings for Q1 2024.